D-4-氨甲基苯丙氨酸 | 1217662-97-9

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苯丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: D-4-氨甲基苯丙氨酸
• 中文别名: 4-氨甲基-D-苯丙氨酸；4-氨甲基-D-苯基丙氨酸
• 英文名称: (R)-2-Amino-3-(4-(aminomethyl)phenyl)propanoic acid
• 英文别名: (2R)-2-amino-3-[4-(aminomethyl)phenyl]propanoic acid
• CAS: 1217662-97-9
• 化学式: C₁₀H₁₄N₂O₂
• 分子量: 194.23
• InChiKey: GNVNKFUEUXUWDV-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  89.3
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Cyclopeptide derivatives
  申请人：Merck Patent GmbH

  公开号：US20020198142A1

  公开（公告）日：2002-12-26

  Compounds of the formula I R—Q—X  I in which R is cyclo-(Arg-Gly-Asp-Z), where Z is bonded in the side chain to Q, or if Q is absent, to X, Q is absent, or is —[CO—R 1 —NH—] m , —[NH—R 1 —CO—] m , —[CO—R 1 —CO—] m , —(CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH—) n , —(NH—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —CO—) n , —(NH—CH 2 CH 2 —O—CH 2 CH 2 —O—CH 2 —CO—) n or —(CO—CH 2 —O—CH 2 CH 2 —O—CH 2 CH 2 —NH—) n —[CO—R 1 —NH—] m , X is —CO—CH═CH 2 , —CO—C (CH 3 )═CH 2 , —NH—CH═CH 2 , —NH—C(CH 3 )═CH 2 or —NH—(CH 2 ) p -SH 10 , Z is in each case independently of one another an amino acid residue or a di- or tripeptide residue, where the amino acids independently of one another are selected from a group consisting of Ala, Asn, Asp, Arg, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val or M, where the amino acids mentioned can also be derivatized, and the amino acid residues are linked to one another in peptide fashion via the &agr;-amino- and &agr;-carboxyl groups, and where M is always present, M is NH(R 8 )—CH(R 3 )—COOH, and R 1 , R 3 , R 8 , m, n and p have the meanings indicated in claim 1, and their salts, can be used as integrin inhibitors, in particular for the treatment of disorders caused by implants, defects, inflammations and of osteolytic disorders such as osteoporosis, thrombosis, cardiac infarct and arteriosclerosis, and also for the acceleration and reinforcement of the integration process of the implant or of the biocompatible surface into the tissue.

  分子式为IR-Q-X的化合物，其中R为环状-(Arg-Gly-Asp-Z)，其中Z与Q或X中的一个相连，如果Q不存在，则与X相连，Q可以不存在，或者为—[CO-R1-NH]m，—[NH-R1-CO]m，—[CO-R1-CO]m，—(CO-CH2-O-CH2CH2-O-CH2CH2-NH-)n，—(NH-CH2-O-CH2CH2-O-CH2CH2-CO-)n，—(NH-CH2CH2-O-CH2CH2-O-CH2-CO-)n或—(CO-CH2-O-CH2CH2-O-CH2CH2-NH-)n-[CO-R1-NH]m，X为—CO-CH═CH2，—CO-C(CH3)═CH2，—NH-CH═CH2，—NH-C(CH3)═CH2或—NH-(CH2)p-SH10，其中Z在每种情况下都是独立的氨基酸残基或二肽或三肽残基，其中氨基酸相互独立地从包括Ala、Asn、Asp、Arg、Cys、Gln、Glu、Gly、His、Ile、Leu、Lys、Met、Phe、Pro、Ser、Thr、Trp、Tyr、Val或M的群组中选择，所述氨基酸也可以是衍生物，并且氨基酸残基通过α-氨基和α-羧基团以肽的方式相互连接，其中M始终存在，M为NH(R8)-CH(R3)-COOH，R1、R3、R8、m、n和p具有权利要求1中所示的含义，以及它们的盐，可用作整合素抑制剂，特别是用于治疗由植入物、缺陷、炎症和骨质疏松等疾病引起的障碍，以及用于加速和加强植入物或生物相容表面与组织的整合过程。
• Inhibitors of the blood-clotting factor xa, production thereof and use of the same
  申请人：Sturzebecher Jorg

  公开号：US20050119190A1

  公开（公告）日：2005-06-02

  The invention relates to novel inhibitors of clotting factor Xa, the preparation and use thereof for therapy, prophylaxis and diagnosis of cardiovascular disorders and thromboembolic events.

  本发明涉及一种新型凝血因子Xa抑制剂，其制备和用途用于治疗、预防和诊断心血管疾病和血栓栓塞事件。
• CYCLOPEPTIDE DERIVATIVES
  申请人：——

  公开号：US20020032306A1

  公开（公告）日：2002-03-14

  The invention relates to compounds of the formula (I) R1 Q1 XQ2 R2, in which: Q1, Q2, each independent of one another, are missing or are NH(CH2)n CO; R1, R2, each independent of one another, are missing or are cyclo(ArgGlyAspZ), wherein Z is missing in the side chain of Q1 or Q2 or if Q1 and/or Q2 are missing, is bound to X, at least one of the groups R1 or R2 always having to be included; X is COR 18 CO, and if R1 Q1 or R2 Q2 are missing is R10, R13, R16, HetCO or a fluorescent pigment residue linked through a CONH, COO, NHC (═S)NH, NHC(═O)NH, SO2 NH or NHCO bond; and Z, R10, R13, R16, R18, Het and n have the meanings given in claim 1. The invention also relates to the salts of said compounds. Said compounds and their salts can be used as integrin inhibitors, in particular for the prevention and treatment of circulatory diseases, thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, angiogenic diseases and in tumor therapy.

  本发明涉及式(I)的化合物，其中：Q1，Q2，互相独立，可以缺失或为NH(CH2)n CO; R1，R2，互相独立，可以缺失或为环状(ArgGlyAspZ)，其中Z在Q1或Q2的侧链中缺失或如果Q1和/或Q2缺失，则与X结合，其中必须始终包括R1或R2中的至少一个基团; X为COR 18 CO，如果R1 Q1或R2 Q2缺失，则为R10，R13，R16，HetCO或通过CONH、COO、NHC(═S)NH、NHC(═O)NH、SO2 NH或NHCO键连接的荧光色素残基; Z，R10，R13，R16，R18，Het和n的含义如权利要求书中所述。本发明还涉及所述化合物的盐。所述化合物及其盐可用作整合素抑制剂，特别用于预防和治疗循环疾病、血栓、心肌梗塞、冠心病、动脉硬化、血管生成性疾病和肿瘤治疗。
• LHRH-II PEPTIDE ANALOGS
  申请人：Linder Karen E.

  公开号：US20120045393A1

  公开（公告）日：2012-02-23

  The invention is directed to analogs of LHRH-II and, more generally, to analogs of the LHRH family in which modifications have been made that confer enhanced binding affinity for LHRH receptors and/or improved metabolic stability. The invention is further directed to methods of targeted therapy and targeted imaging in patients with sex-hormone-related cancers or other LHRH-mediated diseases.

  该发明涉及LHRH-II的类似物，更一般地，涉及LHRH家族的类似物，其中进行了改性以赋予LHRH受体更强的结合亲和力和/或改善代谢稳定性。该发明进一步涉及在患有性激素相关癌症或其他LHRH介导疾病的患者中进行有针对性的治疗和有针对性的成像的方法。
• KINASE INHIBITORS
  申请人：RESPIVERT LIMITED

  公开号：US20160102059A1

  公开（公告）日：2016-04-14

  There are provided compounds of formula I, wherein R 1A to R 1E , R 2 to R 4 , R 5a , L and X 1 to X 3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

  提供了化合物I的公式，其中R1A至R1E、R2至R4、R5a、L和X1至X3具有描述中给出的含义，这些化合物具有抗炎活性（例如通过抑制p38有丝分裂原活化蛋白激酶酶家族的一个或多个成员、Syk激酶以及酪氨酸激酶Src家族的成员之一），并且在治疗中有用，包括在药物组合中，特别是用于治疗炎症性疾病，包括肺部、眼部和肠道的炎症性疾病。